Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis
Authors' conclusion
This disproportionality study identified 25 anticancer drugs significantly associated with CTRCD reporting, including new signals. It highlights discrepancies compared with drugs recommended for cardiac dysfunction evaluation in the 2022 ESC Guidelines. This underscores the importance of including CTRCD as a safety endpoint in cancer studies.
Study context
- Population
- Individual case safety reports in the World Health Organization's VigiBase® database, from the initial report of any anticancer drug until 29 February 2024database reports, 42,828 cancer therapy-related cardiac dysfunction (CTRCD) cases associated with at least one anticancer drug
- Participants
- 36,580,288 reports
- Comparison
- Reporting odds ratios for CTRCD with anticancer drugs
- Outcome
- Anticancer drugs significantly associated with CTRCD reporting
Methodological detailsmultivariable-adjusted analyses, stepwise selection procedure
- Multivariable-adjusted analyses
- Stepwise selection procedure
Main finding
As reported in the abstract
- Anticancer drugs significantly associated with CTRCD reporting
- 25
Further findings
CTRCD reporting with kinase inhibitors
- Associated with kinase inhibitors, including BCR-ABL inhibitors, ibrutinib, and osimertinib
New signals
- New signals for trabectedin, clofarabine, fludarabine, entrectinib, gemtuzumab ozogamicin, and anagrelide
Immune checkpoint inhibitors and anti-VEGF therapies
- Immune checkpoint inhibitors and most anti-vascular endothelial growth factor therapies showed no association with CTRCD
Safety
Death among CTRCD cases
- Death reported
- 20.6% of cases (8833 CTRCD cases)
Original publication
Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis. Eur Heart J Cardiovasc Pharmacother. Published 24 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →